Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine

Kiyoshi Ando, Chiyoko Nishime, Ryo Inoue, Eiko Nishinaka, Kenji Kawai, Koji Urano and Hideki Tsutsumi

The differential effects of dopaminergic drugs with different pharmacological profiles were investigated with respect to spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine (6-OHDA). Three marmosets received infusions of 6-OHDA (either 30 or 40 μg/side) into the bilateral dopamine-rich area running from the substantia nigra to the striatum. The motor activity of the 6-OHDA marmosets was compared with that of three intact marmosets. Following the administration of apomorphine (0.5 and 1 mg/kg, subcutaneously), the 6-OHDA group showed a tendency toward a brief increase in activity counts, suggesting denervation supersensitivity at the dopamine receptors. After the administration of methamphetamine (1 and 2 mg/kg, subcutaneously), the 6-OHDA group showed a significant decrease in activity counts, indicating limited dopamine release from the degenerated neurons. After the administration of 6-OHDA in the marmoset may have preclinical utility as a primate model for investigating the behavioral properties of dopaminergic drugs in brains with dopaminergic neural deficits. Behavioural Pharmacology 28:670–680 Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.

Behavioural Pharmacology 2017, 28:670–680

Keywords: apomorphine, bilateral brain infusion, common marmoset, dopaminergic drugs, 6-hydroxydopamine, L-3,4-dihydroxyphenylalanine, methamphetamine, Parkinson’s disease, spontaneous motor activity

Central Institute for Experimental Animals, Kawasaki, Japan
Correspondence to Kiyoshi Ando, PhD, Central Institute for Experimental Animals, 3-25-12 Tomonachi, Kawasaki, Kawasaki 210-0821, Japan
E-mail: ando@ciea.or.jp

Received 16 May 2017 Accepted as revised 16 September 2017

Introduction

Parkinson’s disease (PD) is an age-related neurodegenerative disorder that is an important and urgent target of studies in the field of basic neuroscience. Such studies will contribute toward elucidation of the pathogenesis of PD and evaluation of possible treatments for this disorder.

Traditionally, neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) have been used to establish PD models in laboratory animals. In primates and certain strains of mice, MPTP is usually administered peripherally. We previously studied the neurobehavioral aspects of the MPTP model of PD in the common marmoset, a small primate with a body size similar to that of a large adult rat (Ando et al., 2008, 2012, 2014). The MPTP marmoset model of PD has also been used by many other groups (Eslamboli, 2005; Jenner, 2009) and a similar model is used in macaques (Nagai et al., 2007). MPTP-treated primates provide a useful in-vivo model of the disease in humans in terms of degenerated dopaminergic neurons and behavioral manifestations. The model is therefore also useful in the preclinical evaluation of various therapies, including drugs, deep brain stimulation (Zhang et al., 2012), and the implantation of dopaminergic neurons induced by stem cells (Emborg et al., 2013; Wolff et al., 2015) as well as induced pluripotent stem cells (Hallett et al., 2015).

In addition to MPTP, 6-OHDA has been used for preclinical studies of PD, particularly in rodents (Ungerstedt, 1968). In contrast to MPTP, 6-OHDA does not penetrate the blood–brain barrier and, therefore, must be infused directly into brain regions when studying specific types of damage to dopaminergic neurons. In rodent models using 6-OHDA, the toxin is generally infused into either the right or the left side of the brain in dopaminergic neural areas, such as the medial forebrain bundle (Baier et al., 2006), where it effectively causes unilateral neural damage. Subsequently, when a dopamine agonist, such as apomorphine, is administered peripherally, rodents

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

0955-8810 Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.

DOI: 10.1097/FBP.0000000000000353
show contralateral circling behavior because of denervation supersensitivity of the dopaminergic receptors in the damaged side (Boules et al., 2001). However, when a dopamine releaser, such as amphetamine, is administered peripherally, the same rodents show ipsilateral circling behavior because of a lower degree of dopamine release from nerve terminals on the damaged side relative to the intact side. Thus, the 6-OHDA rodent model, and specifically, measurements of the direction and the frequency of circling behavior, are useful for qualitative and quantitative assessments of drug action and the behavioral pharmacological properties of novel compounds that are potential treatments for PD (Kirik et al., 1998).

Although most studies have utilized 6-OHDA models using rodents, others have used 6-OHDA models using marmosets (Annett et al., 1990; Eslamboli, 2005; Garea-Rodriguez et al., 2016). In our limited experience using the 6-OHDA marmoset model, ipsilateral circling was observed following an injection of apomorphine, but stable contralateral circling was not observed following an injection of methamphetamine (Ando K, Nishime C and Nishinaka E, unpublished data). However, in the 6-OHDA rat model, we could observe differential circling dependent on apomorphine and methamphetamine (Inaji et al., 2005). Therefore, in the present study, we administered bilateral, rather than unilateral, infusions of 6-OHDA into the brains of marmosets to further study the usefulness of the 6-OHDA marmoset model for understanding the behavioral actions of dopaminergic drugs.

The aim of the present study was to detect differential behavioral effects among dopaminergic drugs with different pharmacological actions in the common marmoset following the induction of mild damage to dopaminergic neurons using 6-OHDA. The dopaminergic drugs tested in the present study included apomorphine (a dopamine receptor agonist), methamphetamine (which releases dopamine from nerve terminals), and L-3,4-dihydroxyphenylalanine (L-DOPA, a dopamine precursor and a therapeutic drug for patients with PD). The acute effects of these drugs on spontaneous motor activity were evaluated in marmosets pretreated with a bilateral infusion of 6-OHDA into the dopamine-rich region running from the substantia nigra to the striatum. The spontaneous motor activity counts of the 6-OHDA model marmosets in their individual living cages were compared with those of intact marmosets that neither received a 6-OHDA infusion nor underwent a sham operation.

In the present behavioral study, which relied in part on objectively measurable motor activity counts, grossly observable behavioral signs were also recorded and the histology of the 6-OHDA infused marmoset brains was analyzed. Together, these procedures provided supplemental data on the effects of the drugs on motor activity.

Finally, the preclinical utility of the 6-OHDA marmoset model as well as its limitations as a primate model of dopaminergic neural degeneration were evaluated. Our results were compared with those from a large number of historically accumulated studies on the MPTP marmoset model.

**Methods**

**Ethics statement**

The present study was carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals published by the National Research Council. The study protocol was reviewed by the Animal Care and Use Committee of the Central Institute for Experimental Animals and approved by the Institute (CIEA approval number: 13016). The criteria used by the committee complied with those mandated by the Japanese Law for the Humane Treatment and Management of Animals. In addition, this study was designed and carried out under the principle of the three Rs (Replacement, Reduction, and Refinement) for the use of experimental animals (Blakemore et al., 2012).

**Subjects**

Healthy adult male common marmosets were obtained from CLEA Japan Inc. (Tokyo, Japan). At the start of the experiment, the body weights and ages of the animals were between 300 and 436 g and they were between 2.8 and 6.8 years of age, respectively. After brain infusion of 6-OHDA, the marmosets were used to investigate the acute behavioral pharmacological effects of dopaminergic drugs on spontaneous motor activity.

During the experimental period, each marmoset was housed in an individual stainless-steel living cage (50 cm high, 30 cm wide, and 48 cm deep) with a wire-mesh floor and walls; each cage was placed in an enclosed box in the same animal room. The animals were supplied with a balanced diet (50 g/day, CMS-1M; CLEA Japan Inc.) and free access to tap water from feed valves. The temperature and humidity in the animal room were 25–26°C and 45–50%, respectively, and the room was illuminated from 08:00 to 20:00 h.

**Bilateral infusion of 6-hydroxydopamine into the brain**

Each marmoset was anesthetized with an intravenous administration of sodium pentobarbital (25 mg/kg of somnopentyl; Kyoritsu Seiyaku Co. Ltd, Tokyo, Japan). Next, the head was placed in a stereotaxic frame designed originally for a rat such that the position of the head was fixed at a horizontal level between the orbital region and the interaural line as a reference position. Then, the skull was exposed and two small holes were drilled over the right and left regions of the brain where dopamine-rich connections run from the substantia nigra to the striatum in the normal marmoset brain. The regions were determined on the basis of the results of a tyrosine hydroxylase (TH) antibody staining study in the stereotaxic atlas of the marmoset brain (Yuasa et al., 2010); positioning from the reference point was +7.9 mm...
of 30 disruption (see the Results section). Therefore, the dose sufficiently and were eating and drinking voluntarily. 

administered subcutaneously until they had recovered (Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan), was dehydration. In addition, an electrolyte fluid, KN1A Sunworld Co. Ltd, Tokyo, Japan) supplements were Dairies Corp., Tokyo, Japan) and Cakesia (Morinyu 6-OHDA, mixed solutions of the Meibalance (7 ml; Meiji marmoset did not eat or drink after the brain infusions of Takeda Pharmaceutical Co Ltd, Osaka, Japan). If a were rubbed with oxytetracyline (terramycin ointment; Seika Pharma Co. Ltd, Tokyo, Japan), and their wounds surgery, the marmosets received intramuscular adminis- 

dental cement was placed in the burr holes, the incision was sutured and closed, and the marmosets were 

for measuring the motor activity counts were similar in the present study and the previous l-DOPA study.

**Drugs**

Apomorphine hydrochloride (Sigma-Aldrich Co.) was dis- solved in physiological saline using an ultrasonic mixing apparatus just before its administration. Solutions of the test doses used in this study (0.5 and 1 mg/kg) were prepared to a volume of 2 ml/kg for each dose. Methamphetamine hydrochloride (Sumitomo Dainippon Pharma Co. Ltd, Osaka, Japan) was dissolved in saline to a concentration of 2 mg/ml, prepared as an original solution, kept in a locked refrigerator, and used within 1 month of its preparation. Solutions of the test doses used in this study (1 and 2 mg/kg) were diluted with saline before each test to an administered volume of 2 ml/kg. To prepare the l-DOPA, neodopast combination tablets (Daichi Sankyo Co. Ltd, Tokyo, Japan) containing 100 mg of l-DOPA and 10 mg of carbidopa were prepared immediately before administration by crushing a single tablet into minute particles and suspending the par- 

ticles in a 2.5% (w/v) Gum Arabic solution using distilled water; each test dose used in this study (10 and 20 mg/kg) was prepared in a volume of 2 ml/kg. The l-DOPA was administered orally using an intragastric tube, designed for use in human infants, that passes the solution into the stom- 

ach of the marmoset through its mouth; a pencil was placed in the mouth beforehand to prevent biting of the tube.

**Daily spontaneous motor activity in the 6-hydroxydopamine marmoset model**

The daily spontaneous motor activity count of each marmoset in its individual living cage was recorded continuously for 24 h in the consecutive days before and just after the bilateral infusion of 6-OHDA into the brain; the activity counts of the intact marmosets, which were neither sham operated and nor administered a 6-OHDA infusion, were recorded in a similar manner. An infrared motion sensor (O'Hara and Co., Tokyo, Japan) attached to the ceiling of each cage detected spontaneous motor activity by measuring spatial shifts in thermal sources (the body parts of the marmosets) and the CIEA ACTSCAN system (Prime Lab Inc., Tokyo, Japan) was used to record and analyze the spontaneous motor activity data.

To obtain additional information, grossly observable behavioral signs in the marmosets were recorded using our dysfunction score system developed for MPTP model marmosets, which consisted of 11 items, including moving tremor, immobility, positional dysfunction, and others (Ando et al., 2008). However, as this scoring system failed to detect many behavioral changes or other unexpected changes in 6-OHDA model marmosets, these data are not reported. Instead, clearly manifested behavioral changes by visual inspection were recorded each time they occurred.

For each drug test, the vehicle was administered first; this was followed by two doses of the drug in ascending order, with at least 1 week between tests. For all subjects, the first saline administration in the apomorphine test was initiated 1–2 months after the bilateral 6-OHDA infusion and the final l-DOPA test (20 mg/kg) was performed 2.5–3.5 months after the 6-OHDA infusion. The spontaneous motor activity counts of the intact marmosets for the l-DOPA test were obtained from a previous study (Ando et al., 2014): the data of three intact marmosets were selected randomly from the data of six marmosets used in the previous study. The experimental conditions for measuring the motor activity counts were similar in the present study and the previous l-DOPA study.

**Immediately before surgery and the infusion of 6-OHDA into the brain of each marmoset in the 6-OHDA group (n = 3), desipramine hydrochloride (40 mg/kg; Wako Pure Chemical Industries Ltd, Osaka, Japan) was administered intraperitoneally to protect the serotonergic and noradrenergic neurons of the animals from 6-OHDA-induced damage while allowing the specific lesioning of dopaminergic neurons. Desipramine hydrochloride was dissolved in physiological saline to a concentration of 2 ml/kg before its administration 1 h before surgery. 6-OHDA hydrochloride (Sigma-Aldrich Co. St Louis, Missouri, USA) was dissolved in distilled water [with ascorbic acid (1 mg/ml) added to prevent the oxidation of 6-OHDA] to a concentration of 1 μg/ml before its infusion into the brain.

The tip of a 50-μl Hamilton syringe needle was placed 7.3 mm from the interaural line, slowly lowered into the brain, and the 6-OHDA solution was infused into the right side of the brain at 40 μg for marmoset OH01 and at 30 μg for marmosets OH02 and OH04. Immediately after the right-side infusion into each marmoset brain, another infusion to the left region at the same dose was performed in a similar manner. The solution was infused manually into each brain at the speed of 1 μl/s and, sub- 
sequently, the needle was withdrawn slowly. The dose of 40 μg in one subject (OH01) produced marked behavioral disruption (see the Results section). Therefore, the dose of 30 μg of 6-OHDA was infused in the other subjects (OH2 and OH4). After both infusions were completed, dental cement was placed in the burr holes, the incision was sutured and closed, and the marmosets were returned to their individual living cages. Following the surgery, the marmosets received intramuscular administrations of ampicillin sodium (20 mg/kg of viccillin; Meiji Seika Pharma Co. Ltd, Tokyo, Japan), and their wounds were rubbed with oxytetracyline (terramycin ointment; Takeda Pharmaceutical Co Ltd, Osaka, Japan). If a marmoset did not eat or drink after the brain infusions of 6-OHDA, mixed solutions of the Meibalance (7 ml; Meiji Dairies Corp., Tokyo, Japan) and Cakesia (Morinyu Sunworld Co. Ltd, Tokyo, Japan) supplements were given by a gavage to compensate for anorexia and dehydration. In addition, an electrolyte fluid, KN1A (Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan), was administered subcutaneously until they had recovered sufficiently and were eating and drinking voluntarily.**
Tyrosine hydroxylase antibody staining in the brain

After the acute drug tests had been completed, the 6-OHDA-treated marmosets were deeply anesthetized with an intraperitoneal administration of sodium pentobarbital (100 mg/kg of somnopentyl; Kyoritsu Seiyaku Co. Ltd, Tokyo, Japan) and euthanized by exsanguina-
tion. An intact (nonoperated) marmoset matched for body weight and age was treated in the same manner as above and used as the control. The brains were removed, fixed in 20% buffered formaldehyde for 5–7 weeks, and embedded in paraffin. Coronal sections prepared at a thickness of 15 μm were obtained from a location 10 mm from the interaural line and 6.1 mm from the Bregma. Only coronal sections were obtained in the present study as supplementary histological information accompanying the behavioral data because the caudate and the putamen could be distinguished clearly in the striatum of the intact marmoset brains. Immunohistochemical staining with a TH antibody (1 : 500, mouse anti-TH MAB318; Merck Millipore Co., Billerica, Massachusetts, USA) was performed using an automated immunostainer (Bond-MAX; Leica Biosystems Co., Mount Waverley, Victoria, Australia), and images were captured and generated using an upright microscope (Axio Imager; Carl Zeiss Inc., Thornwood, New York, USA).

The coronal images of the brains of 6-OHDA-treated marmosets (OH01, OH02, and OH04) and of an intact mar-
moset (CM32) were analyzed quantitatively using NIH ImageJ software (https://imagej.nih.gov/ij/). Each image was captured by the software and evaluated in the following manner: (i) selecting ‘Image→Color→Split Channels’ and using only the blue split image, (ii) setting the length scale in mm, (iii) tracing the outline of the whole coronal brain image as the region of interest (ROI), (iv) selecting ‘Image→Adjust→Threshold’ and adjusting the minimum threshold to 0 and the maximum threshold to 100 because these settings yielded clear images of the striatum in the intact marmoset brain without interference by other areas, and (v) selecting ‘Analyze→Measure’. With these settings, the area of the image detected under the fixed thresholds (in pixels) from the whole coronal brain was calculated in mm². To determine density differences across brain images obtained from different tissue preparations, simplified vali-
dations were performed. Each square area (1.0×1.0 mm) defined as the ROI was placed in the right and left cortex of the same split blue coronal images. These square ROI areas were measured in mm² with or without thresholds.

Statistical analysis

All averaged data are presented as mean±SD. Statistical analyses were carried out only for the dose–effect relation-
ships obtained with the three test drugs with respect to spontaneous motor activity, focusing on comparisons of each drug in the 6-OHDA and intact marmoset groups. These relationships were analyzed using motor activity counts in the 90-min period following drug administration. First, for each drug, the motor activity counts of the 6-OHDA and intact groups were compared in a three-way (groups, drugs, and doses) analysis of variance (ANOVA) and post-hoc Bonferroni tests using the SPSS statistical software package (version 19; IBM Corp., Armonk, New York, USA); P values less than 0.05 were considered to indicate statistical significance. Second, for each drug, the area under the curve (AUC) of the dose–effect relationship, measured as motor activity counts in a 90-min period, was calculated for the two groups. The AUC was calculated for each marmoset for each of the three test doses of each drug using the rectangle method (values of the horizontal x-axis: 1, 2, and 3 for the vehicle, low dose, and high dose, respectively; values of the vertical y-axis: number of motor activity counts for 90-min period). The AUC values of the 6-OHDA and intact groups for each of the three drugs were compared with a two-way (groups×drugs) ANOVA and post-hoc Bonferroni tests using the same statistical package as above.

Results

Influence of bilateral infusion of 6-hydroxydopamine into the brain

For ~1 week following the infusion of 40 μg of 6-OHDA into each side of the brain, marmoset OH01 was fully incapacitated and lay on the floor of its individual living cage and, because it neither drank water nor ate food, was supplied with supplementary food and water, as described in the Methods section. A slight moving tremor in this marmoset was observed episodically for several weeks. Thereafter, the tremor disappeared and visually observed motor activity subsequently increased. No other clear neurological evidence, such as positional dysfunction, or other signs usually present in MPTP-treated marmosets, was observed. On the basis of these behavioral observations of marmoset OH01, 30 μg 6-OHDA infusions into each side of the brain were administered to marmosets OH02 and OH04, instead of the 40 μg administered to marmoset OH01. These two marmosets were also incapacitated for several days after the infusions, but to a much lesser degree than OH01. Neither showed clear neurological signs.

The changes in the daily spontaneous motor activity counts of the three 6-OHDA marmosets are presented in Fig. 1 (upper blocks). The motor activity counts of each marmoset varied across the days before 6-OHDA infusion, but remained within a certain range. Following the 6-OHDA infusions, the daily motor activity counts decreased within a few days or more. Although the activity counts of marmoset OH01 increased progressively for several weeks, the activity counts of marmosets OH02 and OH04 (both with 30 μg of 6-OHDA on each side of the brain) did not show this progressive increase, notwithstanding a transient increase in the counts in marmoset OH04. The spontaneous motor activity counts of the three intact marmosets are also presented in Fig. 1 (lower blocks); these counts were also variable, but remained relatively stable compared with those of the 6-OHDA-treated marmosets.
Acute effects of dopaminergic drugs on spontaneous motor activity in the 6-hydroxydopamine and intact marmosets

**Time-course effect relationship**

The present study examined the acute effects of apomorphine, methamphetamine, and L-DOPA on spontaneous motor activity by comparing the motor activity counts of the 6-OHDA and intact groups during each 30-min period for 180 min after the administration of the drugs. Following the administration of vehicle (saline or gum arabic solution) in the 6-OHDA and intact groups, the mean activity counts in each 30-min period ranged from 188.0 to 848.0 over the 180-min test period (Figs 2–4; left sides). There were no significant increases or decreases in the counts within each vehicle test or across the vehicle tests for the three drugs. Furthermore, there were no significant differences between the 6-OHDA and intact groups in the vehicle tests.

In contrast to the vehicle tests, the administration of apomorphine (0.5 and 1 mg/kg) resulted in higher activity counts in the 6-OHDA group during the 30–60-min period after drug administration compared with the intact group (Fig. 2). The activity counts decreased markedly over time in both groups, but 1 mg/kg of apomorphine produced steeper decreases in the 6-OHDA group than in the intact group.

Methamphetamine at 1 mg/kg increased motor activity counts in a time-dependent manner in the intact group (Fig. 3), whereas 2 mg/kg of methamphetamine resulted in a slight decrease in activity counts over time in this group. Alternatively, in the 6-OHDA group, methamphetamine at both 1 and 2 mg/kg resulted in lower activity counts than obtained in the vehicle test group or the intact group following the same doses.

L-DOPA (10 and 20 mg/kg) did not clearly alter the activity counts of the intact group throughout the
180-min test period compared with the vehicle control (Fig. 4). However, compared with the intact group, L-DOPA (10 and 20 mg/kg) increased the activity counts in the 6-OHDA-treated group, with peaks occurring 30–60- or 60–90-min after drug administration.

**Dose–effect relationship**

Differences in the dose–effect relationships of the three drugs on the motor activity of the 6-OHDA and intact groups are also presented in Fig. 5. For this analysis, the motor activity counts during the 0–90-min period...
following drug administration were totaled to exclude the biphasic effects that were observed during the longer 180-min time period. Compared with the intact group, the 6-OHDA group showed trends toward increased motor activity counts after administrations of apomorphine and L-DOPA and a trend toward decreased motor activity counts after the administration of methamphetamine.

**Statistical analysis of activity counts and area under the curve of spontaneous motor activity**

Data on the dose–effect relationships (Fig. 5) were analyzed statistically in terms of (i) spontaneous motor activity counts and (ii) the AUC on the basis of the dose–effect relationships of the counts. In the analysis of spontaneous motor activity counts, a three-way analysis of variance (groups, drugs, and doses) showed a significant effect of drugs \[F(2,44) = 5.53, P < 0.01, \text{and power } = 0.83\] drugs \(\times\) groups interaction \[F(2,44) = 7.78, P < 0.001, \text{and power } = 0.94\], but no significant effect of groups or doses. The post-hoc Bonferroni tests of motor activity showed significant differences between groups (6-OHDA vs. intact) in the methamphetamine \([F(1,4) = 8.05, P < 0.05, \text{and power } = 0.57]\) and L-DOPA \([F(1,4) = 14.63, P < 0.02, \text{and power } = 0.82]\) tests, but not in the apomorphine test.

In the statistical analysis of the AUC, a two-way (groups and drugs) ANOVA showed a statistically significant difference between the 6-OHDA and intact groups \([F(3,2) = 30.04, P < 0.05, \text{and power } = 0.79]\). The post-hoc Bonferroni tests of the AUC values indicated a significant decrease in the 6-OHDA group treated with methamphetamine versus the intact group \([F(1,4) = 9.07, P < 0.05, \text{and power } = 0.62]\) and a significant increase in the 6-OHDA group in the L-DOPA test versus the intact group \([F(1,4) = 13.98, P < 0.02, \text{and power } = 0.80]\). There were no statistically significant differences between the 6-OHDA and intact groups in the apomorphine test, although the AUC showed a tendency to increase in the 6-OHDA group versus the intact group.

**Gross behavior observation**

In evaluating the utility of the 6-OHDA marmoset model, spontaneous motor activity was used as a primary measure, but gross behavioral changes after the different drug administrations were also recorded. Apomorphine, at both 0.5 and 1 mg/kg, induced head twitches and vomiting in some marmosets without a clear differentiation between the two doses. Methamphetamine at 1 and 2 mg/kg caused hypervigilance in some marmosets, but did not cause behavioral changes in the intact marmosets.

**Immunohistochemical staining**

In addition to assessing the behavioral effects of the drugs, a histological study was carried out by histochemically stained sections...
staining the marmoset brain tissues with TH antibody (Fig. 6). A brain slice from the intact group showed clear indications of dopaminergic neurons in the putamen and caudate of the striatum, whereas in coronal brain slices from the 6-OHDA-treated marmosets (OH01 and OH04), there was a loss of striatal neurons. In the brain tissue sample of 6-OHDA-treated marmoset OH02, there was a slight loss of striatal neurons compared with the two tissue samples of the other 6-OHDA-treated marmosets. These images were digitized and analyzed quantitatively. The striatal area within the thresholds became distinct in the brain of the intact marmoset CM32 and measured 36.7 mm². By contrast, the areas within the same thresholds of the 6-OHDA-treated marmosets OH01, OH02, and OH04 were 12.8, 24.9, and 9.7 in mm², respectively. Thus, the brain areas of all 6-OHDA-treated marmosets were smaller than the area of the intact marmoset, indicating neural loss in the former. In the simplified background validations across each brain tissue image, a 1.0 × 1.0 mm area placed on the right and left sides of the cortex was 0.0 mm² in all four brain tissue images observed at the same thresholds. The mean and SD of the square areas in the split blue images (see the Methods section) without any threshold were 179.9 ± 13.3 mm² in the four brain images (coefficient of variation = 0.074), indicating only small background variability across brain tissue images.

**Discussion**

The primary aim of the present study was to examine the behavioral effects of three typical dopaminergic drugs using 6-OHDA-treated marmosets. Bilateral infusion of 6-OHDA resulted in mild damage to dopaminergic neurons in the marmoset brain. Brain damage was also assessed by a quantitative analysis of TH-stained brain tissues, which showed variable amounts of damage in tissues from the three marmoset brains. Differential effects of the dopaminergic drugs, which differ in their pharmacological actions, on the spontaneous motor activity of the 6-OHDA-treated marmosets versus 6-OHDA-free intact marmosets were found. Thus, 6-OHDA-treated marmosets administered apomorphine tended to show a brief behavioral sensitization that may have been associated with the denervation supersensitivity of dopamine receptors because of the 6-OHDA-induced degeneration of dopaminergic neuroterminals (Kostrzewa et al., 2015). However, supersensitivity at the receptor level is considered to be secondary and to fluctuate dynamically over time, which suggests that this change in sensitivity is subtle. The brief behavioral effects observed in the present study are consistent with this idea, although, because of a lack of statistical significance, it is not possible to firmly connect the behavioral changes to denervation supersensitivity at the receptors. The administration of methamphetamine resulted in a decreased level of motor activity in 6-OHDA-treated marmosets compared with intact marmosets, which suggests limited dopamine release.
from the 6-OHDA-induced degenerated dopaminergic neurons (Balcioglu et al., 2003). This explanation assumes that motor activity is increased by excessive dopamine release within the dopaminergic system of the brain (Hattori et al., 1996). Finally, the administration of L-DOPA resulted in an increased level of motor activity in the 6-OHDA-treated group compared with the intact group, which suggests that exogenous L-DOPA contributes toward dopamine synthesis only in degenerated dopaminergic neurons (Abercrombie et al., 1990).

The present findings indicate that the behavioral effects of the three dopaminergic drugs can be assessed in a sensitive, qualitative, quantitative, objective, automated, and simple manner by comparing the motor activity data of 6-OHDA-treated and intact marmosets without the need to remove the animals from their cages. Measurement of spontaneous motor activity in animals left in their living cages has several advantages over measurements recorded with the animals in external activity test chambers, where they must first become habituated to the new environment. Thus, the motor activity counts of already habituated marmosets are more likely to yield sensitive and clear results (Tamborini et al., 1989).

Support for our choice of the measurement of spontaneous motor activity in the cages comes from our previous study in which we used PET to show that the binding potential of [11C]PE2I, a radioligand for dopamine transporters, in the striatum correlated strongly with spontaneous motor activity (locomotion) in MPTP-treated marmosets. The correlation coefficient between the motor activity count and the binding potential at the putamen in the striatum was 0.97 in five marmosets (Ando et al., 2012). We therefore chose to measure spontaneous motor activity as an indicator of behavioral manifestations in the present study.

Compared with the above-mentioned objective measurements of motor activity counts, the visual inspection of gross behavior on the basis of the score system in the present study could not detect clear and consistent differences in the effects of the drugs between the 6-OHDA and intact groups. By gross behavioral observation recording only clearly manifested changes, such effects as
vomiting after apomorphine and hypervigilance after methamphetamine were observed in both groups of marmosets, whereas naturalistic active movement without hyperexcitation was observed only after L-DOPA administration to the 6-OHDA group. Moreover, these changes after apomorphine and methamphetamine were observed in some marmosets in each group, but never in all three of the 6-OHDA marmosets and, when observed, not in a dose-dependent manner. Nevertheless, the visual inspection of gross behaviors may be an important consideration when used in combination with the objective measurements of spontaneous motor activity so as to not overlook any potential consequences of changes in motor activity.

In the marmoset model used in the present study, 6-OHDA was infused into a dopamine-rich area of the midbrain that, on the basis of the rich TH-stained area reported in the marmoset brain atlas, is considered to be an appropriate target for this toxin (Yuasa et al., 2010). Furthermore, this brain region links the substantia nigra to the striatum. TH staining of the marmoset brains in the present study indicated that the doses of 6-OHDA resulted in relatively mild damage to dopaminergic neurons, albeit with individual variability. In our previous studies, greater damage was observed in the brains of marmosets treated with MPTP, with less individual variability (Ando et al., 2008, 2012).

Variable degrees of brain damage in the 6-OHDA marmosets in this study were observed in the TH-stained coronal sections, as confirmed by a quantitative analysis of the TH-stained area in the striatum. The brains of two 6-OHDA-treated marmosets (OH01 and OH04) were clearly damaged, whereas less damage was detected in the brain of the third marmoset (OH02). Even in the brain of marmoset OH02, however, evident damage was confirmed qualitatively relative to the brain of the intact marmoset (CM32). The two 6-OHDA-treated marmosets with clearly damaged brains had a slow but progressive and temporal recovery in daily spontaneous motor activity after the direct infusions. The marmoset with the less damaged brain (OH02) manifested neither a progressive nor a temporal increase in motor activity counts. The behavioral changes in the three marmosets seemed to correspond with the degree of brain damage, although no consistent tendency in sensitivity changes to the dopaminergic drugs depending on the degree of brain damage could be identified in acute drug tests.

The substantia nigra, as the nucleus from which A9 dopaminergic neurons arise, may be the ideal target area for 6-OHDA infusion, but it is small and an accurate infusion is difficult. However, the striatum seems to be large enough to serve as an infusion target, but this area is the terminal region of neurons from the substantia nigra and consists of the putamen and the caudate, which have different functional roles. The medial forebrain bundle is another potential target area for the infusion of 6-OHDA that has been previously and generally used in rodent and marmoset studies; in this region, the nerve bundles are large enough to be accurately targeted, and the neural tracts extend from the substantia nigra to other dopaminergic neurons, including those in the striatum (Henderson et al., 1998; Iancu et al., 2005). However, as discussed above, we chose the dopamine-rich area of the brain that is directly targeted by 6-OHDA. Our study also showed that dopaminergic neural damage in the marmoset cannot be assessed by TH staining alone, but must be accompanied by further analyses. However, compared with rodent models, there are relatively few studies in which the 6-OHDA marmoset model has been used.

As described previously in the Introduction section, our previous unpublished findings using a marmoset model of unilateral brain infusion of 6-OHDA showed that marmosets clearly show contralateral circling behavior after the administration of dopamine agonists, such as apomorphine, but there is no consistent ipsilateral circling after the administration of methamphetamine. By contrast, using qualitative and quantitative measurements, we clearly observed both types of circling behavior in 6-OHDA-treated rats with unilateral brain damage that were administered apomorphine and methamphetamine (Inaji et al., 2005). The neural networks in the marmoset brain are considered to be more complicated than those in the rodent brain. Therefore, it is possible that the marmoset brain engages various compensatory mechanisms after 6-OHDA-induced damage rather than continuing to rely on degenerated neurons as in the rodent brain. This may explain why there were clear differences in the circling behavior of the rodents but not of the marmosets following the administration of dopamine-releasing drugs (e.g. methamphetamine). Thus, if the primary aim of a study is to assess differential circling behaviors following the administration of dopamine agonists and/or dopamine releasers, a rodent model may be more suitable than a marmoset model. However, if the primary aim is to detect a PD-like syndrome, such as immobility and moving tremors because of clear dopaminergic neural degeneration, the MPTP marmoset model may be more suitable (Eslamboli, 2005; Jenner, 2009). Nevertheless, the 6-OHDA marmoset model may offer several advantages when investigating the functional roles of specific brain areas following the degeneration of dopaminergic neurons. In addition, this model may be useful for other types of research, using behavioral measures other than circling, and may yield novel insights in preclinical studies. Toxin-induced marmoset models of PD have contributed toward the current understanding of this disorder, aided in the evaluation of various treatments for PD, and will contribute as active control models for the development of a transgenic model of marmosets expressing human PD genes (Eslamboli, 2005; Sasaki et al., 2009).
Finally, the present study has several limitations that should be mentioned. First, there were relatively few 6-OHDA-treated subjects ($n = 3$), and more data would have better supported the findings. Second, the phase of neural degeneration associated with 6-OHDA and its compensatory mechanisms is considered to be progressive and variable as time passes; thus, the behavioral testing period after the infusion of 6-OHDA is critical for consistent results. Further studies investigating progressive changes in brain damage are needed to better examine the utility of the 6-OHDA marmoset model. Third, more detailed brain histological and neural investigations are necessary to clarify the reason for variability in the TH-stained data, for example, by focusing on the change in the dopamine transporter sites in the caudate and putamen in these marmoset brains. It would also be interesting to observe whether nerve fiber sprouting did occur in the striatum of the 6-OHDA-treated brain. Fourth, direct infusion of 6-OHDA into the substantia nigra pars compacta of the marmoset brain may be preferable. This may be possible with more skillful infusion technique because, even though body weights are similar, the brain of the marmoset is larger than that of the rat.

Conclusion
The present study identified differential behavioral effects among dopaminergic drugs with different pharmacological actions using the common marmoset with mild damage to the dopaminergic neural system in the brain induced by 6-OHDA. The utility of this marmoset model with bilateral 6-OHDA infusions was shown for the stated purpose of clarifying the behavioral pharmacological properties of dopaminergic drugs.

Acknowledgements
The authors thank Sayaka Ohba for her special technical contribution to the present experiment. The study could not have been carried out without the cooperation of the staff of the Department of Marmoset Research of the CIEA, especially Drs Takashi Inoue and Toshio Ito.

Conflicts of interest
There are no conflicts of interest.

References
Abercrombie ED, Bonatz AE, Zigmond MJ (1990). Effects of L-DOPA on extracelular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525:36–44.
Ando K, Maeda J, Inaji M, Okauchi T, Obayashi S, Higuchi M, et al. (2008). Neurobehavioral protection by single dose L-deprenyl against MPTP-induced parkinsonism in common marmosets. Psychopharmacology (Berl) 195:509–516.
Ando K, Obayashi S, Nogai Y, Oh-Nishi A, Minamimoto T, Higuchi M, et al. (2012). PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson’s disease. PloS One 7:e48371.
Annett LE, Dunnett SB, Martel FL, Rogers DC, Ridley BM, Baker HF, Marsden CD (1990). A functional assessment of embryonic dopaminergic grafts in the marmoset. Prog Brain Res 82:535–542.
Baker PC, Bransia P, Koch R, Schindehutte J, Paulus W, Trenkwalder C (2006). Circadian distribution of motor-activity in unilaterally 6-hydroxy-dopamine lesioned rats. Exp Brain Res 169:283–288.
Balcikoglu A, Zhang K, Tarazi FI (2003). Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study. Neuroscience 118:1045–1053.
Blakemore C, Macarthur Clark J, Nevalainen T, Obergdorfer M, Sussman A (2012). Implementing the 3Rs in neuroscience research: a reasoned approach. Neuron 75:948–950.
Boules M, Warrington L, Fauq A, McCormick D, Richelson E (2001). Antiparkinson-like effects of a novel neurotensin analog in unilaterally 6-hydroxydopamine lesioned rats. Eur J Pharmacol 428:227–233.
Embrogz ME, Zhang Z, Joers V, Brunner K, Bondarenko V, Ohshima S, Zhang SC (2013). Intracerebral transplantation of differentiated human embryonic stem cells to hemiparkinsonian monkeys. Cell Transplant 22:831–838.
Eslambol A (2005). Marmoset monkey models of Parkinson’s disease: which model, when and why? Brain Res Bull 68:140–149.
Garea-Rodriguez E, Esesmaa A, Lindholm P, Schlimbohm C, Konig J, Meller B, et al. (2016). Comparative analysis of the effects of neurotrophic factors CDNF and GDNF in a nonhuman primate model of Parkinson’s disease. PloS One 11:e0149776.
Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, Osborn TM, et al. (2015). Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson’s disease. Cell Stem Cell 16:266–274.
Hattori S, Hashitani T, Matsui N, Nishi H (1996). Dynamic regulation of striatal dopaminergic grafts during locomotor activity. Brain Res 710:45–55.
Henderson JM, Annett LE, Torres EM, Dunnett SB (1998). Behavioural effects of subthalamic nucleus lesions in the hemiparkinsonian marmoset (Callithrix jacchus). Eur J Neurosci 10:689–698.
Iancu R, Mohapel P, Brundin P, Paul G (2006). Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson’s disease in mice. Behav Brain Res 162:1–10.
Inaji M, Okauchi T, Ando K, Maeda J, Naga Y, Yoshizaki T, et al. (2005). Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats. Brain Res 1064:136–145.
Jennr P (2009). From the MPTP-treated primate to the treatment of motor complications in Parkinson’s disease. Parkinsonism Relat Disord 15 (Suppl 4): S18–S23.
Kirk D, Rosenblad C, Bjorklund A (1998). Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastralial 6-hydroxydopamine in the rat. Exp Neurol 152:259–277.
Koszewa JP, Kostrewa RA, Kostrewa RM, Brus R, Nowak P (2015). Perinatal 6-hydroxydopamine to produce a lifelong model of severe Parkinson’s disease. Curr Top Behav Neurosci. doi: 10.1007/7854 2015 396. [Epub ahead of print].
Nagai Y, Obayashi S, Ando K, Inaji M, Maeda J, Okauchi T, et al. (2007). Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography, Synapse 61:809–819.
Sasaki E, Sueimu H, Shimada A, Hanazawa K, Otowa R, Kamioka M, et al. (2009). Generation of transgenic non-human primates with germline transmission. Nature 459:523–527.
Tamborini P, Sigg H, Zbinden G (1989). Quantitative analysis of rat activity in the home cage by infrared monitoring. Application to the acute toxicity testing of acetanilide and phenylmercuric acetate. Arch Toxicol 63:85–96.
Ungerstedt U (1968). 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107–110.
Wolff EF, Mutlu L, Massasa EE, Elsworth JD, Eugene Redmond D Jr, Taylor HS (2015). Endometrial stem cell transplantation in MPTP-exposed primates: an alternative cell source for treatment of Parkinson’s disease. J Cell Mol Med 19:249–256.
Yusa S, Nakamura K, Kohsaka S (2010). Stereotaxic atlas of the marmoset brain with immunohistochemical architecture and MRI images. Tokyo, Japan: National Institute of Neuroscience, National Center of Neurology and Psychiatry.
Zhang J, Wang ZL, Baker KB, Vitek JL (2012). Effect of globus pallidus internus stimulation on neuronal activity in the pedunculopontine tegmental nucleus in the primate model of Parkinson’s disease. Exp Neurol 233:575–580.